Premium Vision Technologies - including VICTUS® Femtosecond Laser Platform with new Swept Source OCT software, Stellaris® PC Vision Enhancement System, TRULIGN® Toric, Crystalens® AO and enVista® Intraocular Lenses - Highlighted through New Promotional Campaign in Booth
FOR RELEASE WEDNESDAY, APRIL 15, 2015
BRIDGEWATER, NJ – Bausch + Lomb, a leading global eye health company, will highlight major upgrades to its surgical platforms during the upcoming Annual American Society of Cataract and Refractive Surgery (ASCRS) Symposium in San Diego, CA (Apr. 17-20). Featuring VICTUS® with the new Swept Source OCT (Optical Coherence Tomography) imaging system, and major advancements in equipment and intraocular lens (IOL) technology, the Bausch + Lomb booth (#1827) will provide surgeons with live demonstrations while they listen to ophthalmic thought leaders speak about surgical innovations. Several scientific podium and poster presentations will provide new data about the company’s pharmaceuticals, intraocular lenses, and surgical equipment. Bausch + Lomb will also host a sponsored scientific symposium focusing on how surgeons can integrate premium technology into their practices to obtain optimal long-term visual outcomes.
“Our whole team at Bausch + Lomb looks forward to sharing our latest, best-in-class ophthalmic surgical and pharmaceutical products with ASCRS attendees,” said Ari Kellen, M.D., head of U.S. Eye Health,
Bausch + Lomb. “As partners with physicians in the advanced care of patients, we are excited to demonstrate our focus on improving both outcomes and practice efficiency with our dual-function technology platforms, the VICTUS® Femtosecond Laser and Stellaris® PC. We also want physicians to experience the broad range of vision our intraocular lenses offer their patients, as well as our portfolio of proprietary pharmaceuticals which treat a wide range of eye conditions. We are dedicated to helping surgeons deliver the best possible long-term vision for their patients while supporting the long-term success of their practices. Our unwavering commitments to innovation, customer support, and clinical education are driven by this shared goal of protecting and enhancing a lifetime of vision for every patient.”
The focus on long-term vision is captured in a new promotional campaign that Bausch + Lomb will unveil during the meeting. “Outcomes that Stand the Test of Time” reflects the full value of the company’s comprehensive surgical portfolio, linking its premium platforms and products into a seamless but versatile solution, which is designed to deliver excellent long-term quality of vision for each patient as well as long-term success for the practice. The innovative brands included in the campaign include the VICTUS® Femtosecond Laser, Stellaris® and Stellaris® PC Vision Enhancement Systems, the Crystalens® AO, TRULIGN® Toric and enVista® IOLs, and Storz® Ophthalmic instruments.
Product Advancements Featured at ASCRS
Earlier in the year, Bausch + Lomb announced its VICTUS® Femtosecond Laser platform received 510(k) clearance from the U.S. Food and Drug Administrations (FDA) for an advanced Swept Source OCT (Optical Coherence Tomography) imaging system and updated software. The new software and imaging system provides surgeons a new intuitive interface that allows faster, simpler customized treatment planning compared to the previous system update and delivers auto-recognition of key landmarks on the eye, including the pupil, anterior capsule and posterior capsule, along with the capsule tilt compensation to maximize lens fragmentation. Attendees can view the latest updates on the VICTUS® platform in addition to the company’s microsurgical systems, the Stellaris® and Stellaris® PC Vision Enhancement system, during live demonstrations in Bausch + Lomb’s booth (#1827).
The company will also highlight its enhanced BLIS™ Injector System, which was first announced in early April. The enhanced BLIS™ is designed exclusively for use with the ® hydrophobic acrylic IOL and now includes a softened and tumble-polished plunger tip that is 2mm longer than the previous design, which helps to facilitate easier placement in the capsular bag.
Twenty new Bausch + Lomb Storz® ophthalmic instruments, which were introduced earlier this year, will be on display at the company’s booth. Many of the instruments were created in collaborations between leading surgeons around the country and Bausch + Lomb engineers and specifically designed to address the continuously evolving demands of premium ophthalmic procedures. The collection of instruments for refractive, cataract and vitreo-retinal surgery include the Pendulum Toric Marker, Carter Cell Sweepers for premium IOLs, and the Palydowycz Finger Manipulator for cataract and femto-surgery. All of the latest innovations from the industry-leading Storz® portfolio will be available for viewing and purchase at the Bausch + Lomb booth (#1827).
In November 2014, Bausch + Lomb acquired the U.S. diagnostics subsidiary, Nicox, Inc., adding the Sjö® diagnostic test kit to its pharmaceuticals portfolio. The Sjö® diagnostic test kit aids in the early detection of Sjögren’s syndrome, a debilitating autoimmune disease that affects millions of people around the world. Historically, Sjögren’s syndrome was a difficult disease to diagnose, however, today eye care professionals can help facilitate early diagnosis using Sjö®, since many individuals who are affected by the disease begin as dry eye patients. Attendees can learn more about Sjö® and Sjögren’s syndrome by visiting Bausch + Lomb’s booth.
Attendees who visit Bausch + Lomb’s booth can also view and learn more about the company’s pharmaceuticals, which include BESIVANCE® (besifloxacin ophthalmic suspension) 0.6%, Lotemax® Gel (loteprednol etabonate ophthalmic gel) 0.5%, Zylet® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension), ZIRGAN® (ganciclovir ophthalmic gel) 0.15%, BEPREVE® (bepotastine besilate ophthalmic solution) 1.5%, ISTALOL® (timolol maleate ophthalmic solution) 0.5%, Retisert® (fluocinolone acetonide intravitreal implant) 0.59 mg, Lacrisert® (hydroxypropyl cellulose ophthalmic insert), VISUDYNE® (verteporfin for injection), and PROLENSA® (bromfenac ophthalmic solution) 0.07%.
Bausch + Lomb is supporting the scientific symposia, “Integrating Premium Technology for Optimal Outcomes,” led by program chair, Y. Ralph Chu, MD, on Sunday, April 19, at the San Diego Convention Center (Hall E, EyeWorld Theater II). The discussion will include the following faculty members: Terry Kim, MD; Ehsan Sadri, MD; Anil Shivaram, MD, and Mitchell C. Shultz, MD. Registration begins at 11:30 a.m. and the program will commence at Noon.
Bausch + Lomb will host a series of interactive programs in its booth led by an impressive and diverse group of highly regarded speakers. The talks begin on Saturday, April 18 and continue through Sunday, April 19. The full schedule includes:
Saturday, April 18:
Sunday, April 19:
Scientific Podium Presentations and Posters
Many of Bausch + Lomb’s key products will be featured in various podium presentations and e-posters including the TRULIGN® Toric posterior chamber IOL, the Crystalens® AO IOL, and the ® hydrophobic acrylic IOL.
The full schedule of podium presentations and posters that will feature Bausch + Lomb’s products includes:
Friday, April 17:
Pepose, Jay. “Randomized Controlled Multicenter Clinical Trial of New Toric Presbyopia-Correcting IOL.” [ASCRS e-Poster Session: KIOSKS, Friday, April 17].
Saturday, April 18:
Mah, Francis S, MD. “Antimicrobial Activity of Ophthalmic Antibiotics Against Bacterial Isolates from the Aqueous and Vitreous Humor.” [ASCRS Paper Session: Room 1A, Saturday, April 18, 1:41 p.m. PDT].
Monday, April 20:
Ang, Robert Edward T. “Visual Outcomes in 3-Year Randomized Clinical Comparison of Accommodating and 2 Multifocal IOLs.” [ASCRS Paper Session: Room 3, Monday, April 20, 8:48 a.m. PDT].
Sheppard, John. “Early Clinical Experience with Hydrophobic Acrylic IOL and Injector System in Patients at Risk for Intraocular Inflammation.” [ASCRS Paper Session: Room 3, Monday, April 20, 1:01 p.m. PDT].
Jackson, Mitchell. “Warm Viscosurgical Device Technique to Facilitate Intraoperative Delivery and Unfolding of Hydrophobic Acrylic IOL.” [ASCRS Paper Session: Room 3, Monday, April 20, 1:24 p.m. PDT].
Epitropoulos, Alice. “Early Clinical Results with a New Toric Presbyopia-Correcting IOL Using Intraoperative Wavefront Aberrometer Guidance.” [ASCRS Paper Session: Room 4, Monday, April 20, 4:07 p.m. PDT].
Stephenson, P. Dee. “Accuracy and Stability of Refractive Astigmatism Correction at Time of Cataract Surgery.” [ASCRS Paper Session: Room 4, Monday, April 20, 4:12 p.m. PDT].
The ®Toric posterior chamber intraocular lens is intended for primary implantation in the capsular bag of the eye for the visual correction of aphakia and postoperative refractive astigmatism secondary to removal of a cataractous lens in adult patients with or without presbyopia who desire reduction of residual refractive cylinder with increased spectacle independence and improved uncorrected near, intermediate and distance vision.
About enVista Intraocular Lens
The enVista intraocular lens is indicated for primary implantation for the visual correction of aphakia in adult patients in whom the cataractous lens has been removed. The lens is intended for placement in the capsular bag.
About Bausch + Lomb:
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing, and restoring people’s eyesight. Our core businesses include ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. We develop, manufacture and market one of the most comprehensive product portfolios in our industry with products available in more than 100 countries.
Visudyne is a trademark of Novartis AG under license.
Zirgan is a trademark of Laboratoires Théa Corporation under license.
All other ®/™ are trademarks of Valeant Pharmaceuticals, Inc. or its affiliates.
© 2015 Bausch & Lomb Incorporated
News Media Contacts:
Public Relations Product Manager, Bausch + Lomb
(585) 338-8095 or email@example.com
BioComm Network on behalf of Bausch + Lomb
(714) 273-2937 or theitmann@BioCommNetwork.com
The website you are about to visit is not affiliated with Bausch + Lomb Incorporated. Bausch + Lomb is not responsible for the content, format, maintenance, or policies of the website you are about to enter and does not monitor non-affiliated websites for accuracy. Links to non-affiliated websites are provided as a convenience; they do not constitute an endorsement or support of any programs, products, or services associated with the website.